Risk factors associated with requiring invasive mechanical ventilation in patients with SARS-CoV-2 infection: experience in a private hospital in Mexico City.

Garibay-Vega B.R., Castillo-Alvarez J.L., Barragan-Reyes A., Bay-Sansores D., Pulido-Enriguez J., Cabrera-Ruiz M.L. Aguilar-Zapata D., Reyes-Mar J., Soto Ramirez L.E., Luis³. Fundación Clínica Médica Sur

were

Introduction

The clinical presentation of SARS-CoV2 disease from ranges asymptomatic respiratory infection to acute respiratory distress syndrome. Risk factors upon hospital admission associated with the need for invasive mechanical ventilation are not well documented.

In this study we evaluated the relationship between clinical risk factors and inflammation markers associated to the need of invasive mechanical ventilation (IMV) support during hospitalization.

Method

185 hospitalized patients with confirmed COVID-19 (PCR-RT) during March 15 to June 15 2020 were enrolled and classified bv the requirement of IMV or not (No-IMV). Comorbidities were recorded.

Inflammation	markers	
requested at the admission.		

Results

During our study we found 65 patients (35%) IMV, 120 (65%) No-IMV. The most common clinical features associated with IMV were male sex, age> 65 years, obesity and high blood pressure. (Table 1). inflammation Elevated markers associated to IMV were a D-dimer (> 1000) and troponin (> 1). (Table 2).

Table 1. Clinical features	IMV (65)	No-IMV (120)
Obesity (BMI >30)	17 (26%)	27 (22%)
Diabetes Mellitus	10 (15%)	19 (15%)
High blood pressure	18 (27%)	26 (21%)
Chronic lung disease	1 (1.5%)	6 (5%)
Immunosuppressi on	2 (3%)	7 (5.8%)
Age >65	39 (60%)	17 (14%)
Male sex	51 (78%)	74 (62%)

Table 2.	IMV (65)	No-IVM (120)
C-reactive protein	12	29 (24%)
>200	(18%)	
D Dimer >1000	17	31 (25%)
	(26%)	
Lymphocyte level	32	71 (59%)
<1.0 × 10 ⁹	(49%)	
Leukocyte level	8 (12%)	27
>11.0 x 10 ⁹		(22.5%)
Ferritin	32	72 (60%)
>400 (Male)	(49%)	
>150 (female)		
Procalcitonin >0.5	7 (10%)	18 (15%)
Troponin >1	12	10 (8.3%)
	(18%)	

Conclusion

This studv showed high the proportion of obesity, hypertension and advanced age among patients who required IMV associated with SARS-CoV2 infection. The presence of elevated D-dimer and troponin on admission are associated with more presentations severe and requirement for IMV.

Bibliography

1. Furong Zenga, Yuzhao Huangc, Ying Guoa Et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. International Journal of Infectious Diseases 96 (2020) xxx-xxx.

2. Carlos D. Crisci, Ledit R. F. Ardusso, Antonela Mossuz. A Precision Medicine Approach to SARS-CoV-2 Pandemic Management. Curr Treat Options Allergy 2020.

3. Sonja Chiappetta, Arya M. Sharma, Vincenzo Bottino. COVID-19 and the role of chronic inflammation in patients with obesity. International Journal of Obesity 2020.

4. Ranganath Muniyappa[,] Sriram Gubbi. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020 May 1;318(5):E736-E741.

March 2020.

6. Zhe Zhua, Ting Caib, Lingyan Fan. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. International Journal of Infectious Diseases 95 (2020) 332-339

7. Fei Zhou, Ting Yu, Ronghui Du. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.

8. Jing Yang, Ya Zheng, Xi Gou, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May; 94: 91-95.

9. Arthur Simonnet, Mikael Chetboun, Julien Poissy. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 2020.

10. Glen Huang, Alex J Kovalic, Christopher J Graber. Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity.



5. Wenhua Liang[,] Weijie Guan, Ruchong Chen. Cancer Patients in SARS-CoV-2 Infection: A Nationwide Analysis in China. The Lancet oncology Vol 21

drpaulocastanedam@hotmail.com brian131820@gmail.com